Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Vivos Therapeutics closed its acquisition of an 11% fully diluted equity stake in SOD Sciences plus a 50% undivided interest in SOD's pseudohypoxia early-warning test, paying no cash — instead issuing 12,000 Series C Convertible Preferred shares with a $12 million stated value. The deal is expected to add more than $10 million to stockholders' equity, which the company believes would cure its previously disclosed Nasdaq minimum stockholders' equity deficiency under Listing Rule 5550(b)(1) — though regaining compliance remains subject to Nasdaq's review.
Key figures
- Deal Value Usd
- 12000000
- Aha patients
- 325000
- Aha facilities
- 3000
- Test ownership
- 50% undivided co-ownership
- Conversion price
- 0.15
- Sod equity stake
- 11% fully diluted
- Max conversion shares
- 80000000
- Preferred shares issued
- 12000
- Expected equity increase
- 10380000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.